Keywords: Treatment Response, Quantitative Imaging, Multi-Center and Multi-Vendor Platform, DCE-MRI, Breast Cancer, Therapy Response, Ktrans
Motivation: Determine best-practice quantitative DCE-MRI for predicting breast cancer (BC) response to neoadjuvant chemotherapy (NAC) in a multi-center (MC) and multi-vendor platform (MP) setting.
Goal(s): Evaluate effects of different pharmacokinetic analysis approaches on Ktrans and its predictive performance.
Approach: 15 BC patients treated with NAC underwent longitudinal DCE-MRI at 3 sites using 3T systems from 3 vendors. Variations in analysis included Tofts model vs. Shutter-Speed model (SSM), ROI- vs. voxel-based analysis, and using fixed vs. measured R10.
Results: Different analysis approaches resulted in significantly different Ktrans, with SSM Ktrans from voxel-based analysis using fixed R10 showing highest predictive accuracy for response.
Impact: Voxel-based SSM analysis using fixed R10 takes advantage of greater range of SSM Ktrans changes in response to therapy, mitigates R10 measurement errors, and may be the best-practice quantitative DCE-MRI for predicting NAC response in a MC and MP setting.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords